Skip to main content
main-content

Medicine Matters oncology

B-cell lymphoma

  • Adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after two or more prior lines of therapy

Cervical cancer

  • Patients with recurrent or metastatic disease and tumors expressing PD-L1 (TPS ≥1), with progression on or after chemotherapy

Classical Hodgkin lymphoma

  • Adult and pediatric patients with refractory disease, or those who have relapsed after ≥3 prior lines of therapy

Gastric cancer

  • Recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma patients with tumors expressing PD-L1

Head and neck squamous cell cancer

  • Patients with recurrent or metastatic squamous cell carcinoma that has progressed on or after platinum-containing chemotherapy

Non-small-cell lung cancer

  • Advanced-stage patients with high PD-L1 expression and no EGFR or ALK mutation
  • (In combination with chemotherapy) Advanced nonsquamous NSCLC patients with no EGFR or ALK mutation

Melanoma

  • Patients with advanced or unresectable disease following progression on previous therapy

Urothelial carcinoma

  • Patients with locally advanced or metastatic disease and progression during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy